Fourth quarter 2025 revenue was $43.9 million, a 25% increase compared to $35.2 million in the prior year. Full year 2025 revenue was $138.9 million, a 1% increase compared to $137.4 million in the prior year. Adjusted cash usage for Q4 2025 was $3.0 million, and for the full year 2025 was $30.9 million. The company ended the fourth quarter with $121.6 million in cash, cash equivalents, marketable securities, and restricted cash, exceeding its guidance of $120 million. Quanterix has implemented $74 million of its $85 million cost synergy target related to the Akoya acquisition, with 94% of integration milestones complete. A 510(k) premarket notification was submitted to the FDA in January 2026 for its multi-analyte algorithmic blood test for Alzheimer's disease. The Centers for Medicare & Medicaid Services (CMS) established a reimbursement rate of $897 for Quanterix's LucentAD Complete test. 13 new assays were launched in 2025, including two new Simoa tau assays and two new Phenocode Discovery panels. Material weaknesses in internal control over financial reporting have been remediated. For 2026, the company expects revenues of $169 million to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49-53%. Quanterix anticipates achieving cash flow breakeven performance in the second half of 2026 and expects to exit the year with approximately $100 million in cash and no debt.